Products & Services
Overview
Catalyzing the next wave of therapeutic development and patient care with ultra-sensitive ctDNA-MRD detection
Our products and services provide a comprehensive solution to academic and biopharma collaborators, allowing access to both our circulating tumor DNA-based minimal residual disease (ctDNA-MRD) testing and our regulatory diagnostic expertise to optimize exploratory research, clinical trials, and diagnostic development programs.
Products & assays
Foresight CLARITY™ MRD B-cell Lymphoma Platform
A minimal residual disease lab-developed test (LDT) that utilizes a fixed panel for ultra-sensitive relapse and recurrence detection in B-cell lymphoma.
Foresight CLARITY™ MRD Solid Tumor Platform
A personalized, ultra-sensitive minimal residual disease assay for exploratory research in solid tumor cancers.
EXPERT services
CDx Development
Seamlessly execute MRD-driven strategies from clinical trials through companion diagnostic development with Foresight Diagnostics as your research, regulatory, and commercialization partner.
Clinical Trial Execution
Partner with our regulatory experts with a history of >100 device and diagnostic approvals and access our centralized, CLIA-registered lab to integrate Foresight CLARITY™ MRD as an endpoint or patient enrollment biomarker in clinical trials.
Translational Research
Interrogate the relationship between MRD and therapeutic response to drive drug development and novel personalized treatment paradigms.
Advance and accelerate your clinical research with ultra-sensitive ctDNA-MRD detection
We help our partners at every stage – from study design to custom bioinformatics and the interpretation of results. This allows us to customize the application of our MRD technology to maximize project or trial success.
